12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IMO-2125: Preliminary Phase I data

Preliminary data from a Phase I trial in 60 treatment-naïve patients with chronic HCV genotype 1 infection showed that subcutaneous IMO-2125 plus Copegus ribavirin was well tolerated with no treatment-related...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >